Hyderabad: Raghava Life Sciences (RLS) has received the drug control body’s approval to manufacture and market the Favipiravir bulk drug.
Hyderabad-based active pharmaceutical ingredients(APIs) company Raghava Life Sciences said it has been in talks with at least eight buyers, including a few overseas companies, to supply the antiretroviral Favipiravir, which is currently being tested for treatment of coronavirus in several countries including India.